Edition:
United States

Ironwood Pharmaceuticals Inc (IRWD.OQ)

IRWD.OQ on NASDAQ Stock Exchange Global Select Market

17.10USD
22 Mar 2017
Change (% chg)

$0.15 (+0.88%)
Prev Close
$16.95
Open
$17.03
Day's High
$17.13
Day's Low
$16.89
Volume
253,862
Avg. Vol
382,792
52-wk High
$18.51
52-wk Low
$9.07

Latest Key Developments (Source: Significant Developments)

Ironwood pharmaceuticals qtrly loss per share $0.09
Tuesday, 21 Feb 2017 04:01pm EST 

Ironwood Pharmaceuticals Inc : Qtrly loss per share $0.09 . Ironwood Pharmaceuticals Inc - ironwood expects 2017 research and development expenses to be in range of $145 million to $160 million. . Qtrly non-gaap loss per share $0.12 . Ironwood Pharmaceuticals Inc - expects combined allergan and ironwood total 2017 marketing and sales expenses for linzess to be in range of $250 million to $280 million . Q4 earnings per share view $-0.24, revenue view $76.9 million -- Thomson Reuters I/B/E/S .Expects to use less than $100 million in cash for operations in 2017.  Full Article

Astellas and Ironwood report positive top-line results from phase III Linaclotide trial in Japan
Sunday, 29 Jan 2017 07:00pm EST 

Astellas Pharma Inc <4503.T>: Astellas and Ironwood report positive top-line results from phase III Linaclotide trial for patients with chronic constipation conducted in Japan . Says Linaclotide is approved in Japan as first prescription treatment for adults with irritable bowel syndrome with constipation . Says patients in phase III cc trial in Japan continue to receive open-label Linaclotide for an additional 52 weeks . Astellas Pharma -top-line trial results indicate that linaclotide-treated patients showed statistically significant improvement compared to placebo-treated patients .Says most common adverse event reported in this trial was diarrhea.  Full Article

U.S. FDA approves 72 mcg dose of linzess® (linaclotide) for adults with chronic idiopathic constipation
Thursday, 26 Jan 2017 07:01am EST 

Allergan Plc : Says new dose is expected to be available in q1 of 2017 .U.S. Food and Drug Administration approves 72 mcg dose of linzess® (linaclotide) for adults with chronic idiopathic constipation.  Full Article

Ironwood Pharma Q2 adj shr loss $0.16
Thursday, 4 Aug 2016 04:25pm EDT 

Ironwood Pharmaceuticals Inc : Ironwood pharmaceuticals provides second quarter 2016 investor update . Q2 gaap loss per share $0.15 . Q2 revenue $54.4 million versus i/b/e/s view $55.5 million . Q2 non-gaap loss per share $0.16 . Q2 earnings per share view $-0.15 -- Thomson Reuters I/B/E/S . Allergan and ironwood continue to expect total 2016 marketing and sales expenses for linzess to be in range of $230 million to $260 million . Says continues to expect to use less than $70 million in cash for operations in 2016 . Q2 earnings per share view $-0.15, revenue view $55.5 million -- Thomson Reuters I/B/E/S Further company coverage: [IRWD.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Allergan says supplemental NDA for 72 mcg Linaclotide accepted for FDA review
Thursday, 9 Jun 2016 08:01am EDT 

Allergan Plc : FDA prescription drug user fee act (PDUFA) target action date is expected to occur in early 2017 . FDA accepted for review SNDA for 72 mcg dose of Linaclotide for use in treatment of adults with chronic idiopathic constipation .Ironwood and Allergan announce supplemental new drug application for 72 mcg Linaclotide in chronic idiopathic constipation has been accepted for FDA review.  Full Article

Ironwood Pharmaceuticals Q1 gaap loss per share $0.09
Monday, 9 May 2016 04:05pm EDT 

Ironwood Pharmaceuticals Inc : Ironwood on track to achieve positive cash flow in 2018 . Ironwood pharmaceuticals provides first quarter 2016 investor update . Q1 non-gaap loss per share $0.08 . Q1 gaap loss per share $0.09 . Q1 revenue $66 million versus i/b/e/s view $53.6 million .Q1 earnings per share view $-0.13 -- Thomson Reuters I/B/E/S.  Full Article

Ironwood Reports Positive Top-Line Data from Phase II Trial of Linaclotide in Adult Patients With Opioid-Induced Constipation
Monday, 30 Nov 2015 08:00am EST 

Ironwood Pharmaceuticals Inc :Reports positive top-line data from phase II trial of linaclotide in adult patients with opioid-induced constipation.Phase II clinical trial of linaclotide conducted in adults with opioid-induced constipation (oic) met its primary endpoint.Data indicate linaclotide-treated patients showed statistically significant improvement for pre-specified primary endpoint.Says Ironwood and Allergan will make a decision regarding advancement of the oic program.Says companies expect data from the linaclotide colonic release phase iib trial in the second half of 2016.  Full Article

Ironwood Pharmaceuticals initiates clinical studies of soluble guanylate cyclase stimulators IW-1973 and IW-1701
Tuesday, 3 Nov 2015 08:00am EST 

Ironwood Pharmaceuticals:Says initiates clinical studies of soluble guanylate cyclase stimulators IW-1973 and IW-1701.Says data from phase IA study with IW-1701 are expected in H1 2016.Says data from phase IB study with IW-1973 expected in H2 2016.  Full Article

Ironwood Reports positive top-line results from phase III Trial of 72 mcg Linaclotide in Adults with Chronic Idiopathic Constipation
Tuesday, 13 Oct 2015 04:01pm EDT 

Ironwood Reports:Says that Phase III clinical trial of its 72 mcg dose of linaclotide in adults with chronic idiopathic constipation (CIC) met the primary endpoint. Ironwood and partner Allergan plc intend to submit a supplemental new drug application to the U.S. FDA in the first half of 2016.Linaclotide is currently approved by the FDA as a 145 mcg capsule to be taken once per day for the treatment of adults with CIC and as a 290 mcg capsule to be taken once per day for the treatment of adults with irritable bowel syndrome with constipation (IBS-C).Both the 72 mcg and 145 mcg linaclotide doses were generally well-tolerated in this trial.Rates of diarrhea and of discontinuations due to diarrhea were lower for the 72 mcg dose than the 145 mcg dose in this trial.Says majority of diarrhea cases reported were characterized as mild in severity.  Full Article

Ironwood Pharmaceuticals, Inc and Allergan enter agreement
Wednesday, 5 Aug 2015 09:25am EDT 

Ironwood Pharmaceuticals, Inc:Ironwood and Allergan enter agreement to co-promote viberzi for irritable bowel syndrome with diarrhea (ibs-d) in the U.S.Says Allergan will be responsible for all other costs relating to the commercialization of viberzi.Says linzess will remain the first-position product for the Ironwood sales team.Says clinical sales specialists will detail viberzi to 25,000 health care practitioners to whom they currently detail linzess and cologuard.Says co-promotion will begin as soon as viberzi is commercially available.  Full Article

More From Around the Web

BRIEF-Ironwood pharmaceuticals qtrly loss per share $0.09

* Ironwood Pharmaceuticals Inc - ironwood expects 2017 research and development expenses to be in range of $145 million to $160 million.